Abstract
Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Current Neuropharmacology
Title: Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity
Volume: 9 Issue: 1
Author(s): D. E. Dluzen, J. L. McDermott, M. Bourque, T. Di Paolo, A. S. Darvesh, A. B. Buletko and N. J. Laping
Affiliation:
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Abstract: Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Export Options
About this article
Cite this article as:
E. Dluzen D., L. McDermott J., Bourque M., Di Paolo T., S. Darvesh A., B. Buletko A. and J. Laping N., Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017399
DOI https://dx.doi.org/10.2174/157015911795017399 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Individual Differences in Vulnerability to Drug Abuse: The High Responders/Low Responders Model
CNS & Neurological Disorders - Drug Targets Quality of Life of Children with Type 1 Diabetes: A Systematic Review
Current Diabetes Reviews Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Cyclooxygenase Inhibition and Atherothrombosis
Current Drug Targets Galanthum nivalis Extract is Neurologically Active and Improves Anxiety and Social Interactions in Mesocricetus auratus
The Natural Products Journal New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Editorial: From Research to Clinical Practice in Adolescent Psychiatry
Adolescent Psychiatry Lipophilic Analogs of Thioflavin S as Novel Amyloid-Imaging Agents
Current Alzheimer Research Meet Our Editor
Current Gene Therapy Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics
Current Psychiatry Reviews Fighting Against Alzheimer's Disease: Synthesis of New Pyrazoline and Benzothiazole Derivatives as New Acetylcholinesterase and MAO Inhibitors
Letters in Drug Design & Discovery Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia
Current Neuropharmacology Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors
Current Drug Safety Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer’s Disease Therapy
Current Alzheimer Research Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Preface:
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Dimerization of C-terminal Truncations of α-synuclein and its Effect on the Aggregation Propensity: A Potential of Mean Force Study
Current Chemical Biology Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design